Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events

Medicilon Events

Hot information:
Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Apr 21,2021
Medicilon assists HitGen's HG381 to be approved as China's first clinical STING agonist
On April 8, 2021, the clinical trial application of HG381 for injection, developed by HitGen, was approved by National Medical Products Administration (NMPA).  HG381 for
More
Medicilon assists HitGen's HG381 to be approved as China's first clinical STING agonist
Apr 08,2021
Medicilon will participate 2021 AACR Virtual Annual Meeting
#Medicilon will exhibit the 2021 AACR Virtual Annual Meeting from April 10-15.  Please visit our virtual booth for more information on our oncology and preclinical
More
Medicilon will participate 2021 AACR Virtual Annual Meeting
Mar 29,2021
Medicilon assists Livzon Pharmaceuticals Group to obtain the clinical approval of novel coronavirus vaccine V-01
Livzon Pharmaceutical Group Inc. (Livzon) obtained a "novel coronavirus recombinant protein vaccine” (V-01) clinical trial approval from the National Medical Products Administration (NMPA) (Batch No.
More
Medicilon assists Livzon Pharmaceuticals Group to obtain the clinical approval of novel coronavirus vaccine V-01
Mar 08,2021
Medicilon will participate 2021 SOT Virtual Annual Meeting
Medicilon will exhibit the 2021 SOT Virtual Annual Meeting from March 12-26.  Please visit our virtual booth to meet our VPs, Dr. Frank Wang, Dr.
More
Medicilon will participate 2021 SOT Virtual Annual Meeting
Feb 25,2021
Medicilon assists TransThera to obtain the Chinese IND for the VAP-1 inhibitor TT-01025, which has the first human subject in the USA
On February 22, 2021, Nanjing TransThera Biosciences Co., Ltd. ("TransThera”) and the life science company of South Korea's LG Chem ("LG Chem”) jointly announced the
More
Medicilon assists TransThera to obtain the Chinese IND for the VAP-1 inhibitor TT-01025, which has the first human subject in the USA
Feb 10,2021
Happy Chinese New Year
Thank you for your business, support and partnership in 2020!  Medicilon appreciates working with you and hope that the coming year will bring you happiness
More
Happy Chinese New Year
Feb 08,2021
3D011-08 from 3D Medicines was approved of conducting clinical trials
Jan 29th, 2021 – CDE announced that the innovative drug, 3D011-08 from 3D Medicines, was approved of conducting clinical trials. It indicates that 3D Medicines
More
3D011-08 from 3D Medicines was approved of conducting clinical trials
Feb 08,2021
Xuanzhu Biotech Announced the Clinical Trial Approval of XZP-5610
Jan.27, 2021 – Xuanzhu Biotech announced that their XZP-5610, a new treatment for NASH (non-alcoholic steatohepatitis), was approved of clinical trials by China NMPA. XZP-5610
More
Xuanzhu Biotech Announced the Clinical Trial Approval of XZP-5610
Jan 13,2021
Medicilon was Awarded the Excellent Academician and Expert Workstation of Shanghai and Pudong New Area
Recently, Shanghai Medicilon was awarded the title of "Excellent Expert Workstation” by the Shanghai Academician and Expert Workstation Guidance Office and the title of "2020
More
Medicilon was Awarded the Excellent Academician and Expert Workstation of Shanghai and Pudong New Area
Jan 04,2021
Medicilon's Top 10 Greatest Achievements in 2020
Medicilon embodies its motto of being "Innovation-driven, quality-focused" and keeps on maintaining and improving its technology and quality of services.
More
Medicilon's Top 10 Greatest Achievements in 2020
Jan 01,2021
Medicilon's pharmacology models for inflammatory-immune diseases
Inflammatory immune diseases have gained much attention as the incidence has grown bigger each year. The diseases can affect many parts of human bodies and
More
Medicilon's pharmacology models for inflammatory-immune diseases
Dec 25,2020
Medicilon is Listed as the 2020 TOP10 Innovation CRO in China
Dec.20, 2020, Hebei—The 13th China Pharmaceutical Strategy Conference 2020 was held successfully. The conference presented the list of "the 2020 TOP10 Innovation CRO in China”.
More
Medicilon is Listed as the 2020 TOP10 Innovation CRO in China